E-poster No. / 壁報編號

C03

Title / 題目

First Author / 第一作者

Sheng-Fan Wang

Institution / 單位

Department of Pharmacy, Taipei Veterans General Hospital; Department and Institute of Pharmacology, College of Medicine, National Yang-Ming Chiao-Tung University

Audio / 音訊檔

Author Group / 作者群

Sheng-Fan Wang1,2, Chian-Ying Chou1#, Yi-Wen Chao3#, Tzu-Kuan Chan3#, Wan-Yu Yeh4, Chern-En Chiang5, Chen-Huan Chen6,7,8, Hsin-Chen Lee2, Ling-Ming Tseng6,9, Yuh-Lih Chang1, Hao-Min Cheng6,7,8*, Chun-Yu Liu6,9,10*

Author Group Institution/ 作者群單位

1. Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan. 2. Department and Institute of Pharmacology, College of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan. 3. Department of Pharmacy, College of Pharmaceutical Sciences, National Yang-Ming Chiao-Tung University, Taipei, Taiwan. 4. Center for Evidence-based Medicine, Taipei Veterans General Hospital, Taiwan. 5. General Clinical Research Center, Taipei Veterans General Hospital, Taiwan. 6. School of Medicine, College of Medicine, National Yang-Ming Chiao-Tung University, Taiwan. 7. Department of Medical Education, Taipei Veterans General Hospital, Taiwan. 8. Institute of Public Health and Community Medicine Research Center, National Yang-Ming Chiao-Tung University School of Medicine, Taiwan. 9. Comprehensive Breast Health Center, Department of Surgery, Taipei Veterans General Hospital, Taiwan. 10. Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taiwan.

Category / 主題分類

Clinical Research

Keyword / 關鍵字

CDK4/6 inhibitors, hormone receptor-positive, HER2-negative, advanced breast cancer, PIK3CA mutation, meta-analysis